Fresenius Medical Care AG & Co. KGaA, a Bad Homburg, Germany-based provider of dialysis products and services, reported the creation of the Global Medical Office, which will seek to further advance the application of clinical science and facilitate the exchange of knowledge across the company's global network to ensure high quality outcomes for patients worldwide. The new office will be led by Frank Maddux, who was appointed global chief medical officer.
Gtcr LLC, a Chicago-based private equity firm, entered a partnership with Gregory Lucier, former chairman and CEO of Nuvasive and Life Technologies, to form Corza Health Inc. The new company, headquartered in San Diego, will focus on acquiring companies and assets as part of a strategy to build a health care business with a focus on the broader life sciences and medical technology sector. Gtcr will invest in Corza Health from Gtcr Fund XII, a private equity fund with $5.25 billion of equity capital commitments. Lucier will serve as CEO of Corza Health and make an investment of an undisclosed amount.
Nevro Corp., a Redwood City, Calif.-based maker of devices for the treatment of chronic pain, reported an agreement with stockholder Broadfin Capital LLC, in which Broadfin will vote all of its shares in favor of each of the company's board nominees at the 2019 annual meeting. Broadfin will also abide by customary standstill provisions and voting commitments. Nevro reported that Keith Grossman has been appointed president and CEO, as well as a member of the board, effective March 19. Grossman succeeds Rami Elghandour, who has stepped down. Nevro also appointed two new independent directors, Elizabeth Weatherman and Kevin O'Boyle, effective immediately, and accepted the resignation of Ali Behbahani as a director. Following the changes, the Nevro board consists of nine members. Nevro said it is suspending revenue guidance while it assesses the business under its new leadership.
Spectral Medical Inc., a Toronto-based developer of a treatment for patients with endotoxemic septic shock guided by a companion diagnostic, entered an agreement with Infomed SA, of Geneva, Switzerland, to extend its license for the continuous renal replacement therapy (CRRT) market to include the home-dialysis market in the U.S. and Canada. As part of the transaction, Spectral transferred in its Renal Replacement Therapy business to a newly created wholly owned subsidiary to be run by Gualtiero Guadagni. That subsidiary will be focused on the commercial development of Sami, Spectral's proprietary CRRT machine, as well as on the regulatory development of a home hemodialysis machine based on the same platform.